Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension

International Journal of Cancer

Volumn 79, Issue 1, 1998, Pages 96-101

  Gohji, Kazuo ^a   Fujimoto, Noboru ^b   Hara, Isao ^a   Fuii, Akio ^c   Gotoh, Akinobu ^a   Okada, Hiroshi ^a   Arakawa, Soichi ^a   Kitazawa, Sohei ^a   Miyake, Hideaki ^a   Kamidono, Sadao ^a   Nakajima, Motowo ^d  

^a KOBE UNIVERSITY   (Japan)

^b FUJI CHEMICAL INDUSTRIES LTD   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^d Oncology Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A;

ADULT; AGED; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DISEASE COURSE; ECHOGRAPHY; ENZYME ANALYSIS; ENZYME IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; STATISTICAL ANALYSIS;

AGED; BONE NEOPLASMS; GELATINASES; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032548966     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980220)79:1<96::AID-IJC18>3.0.CO;2-F     Document Type: Article

References (34)

1. BENSON, M.C., WHANG, I.S., PANTUCK, A., RING, K., KAPLAN, S.A., OLSSON, C.A. and COONER, W.H., Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol., 147, 815-816 (1992).
2. BOAG, A.H. and YOUNG, I.D., Increased expression of the 72-kda type IV collagenase in prostatic adenocarcinoma: demonstration by immunohistochemistry and in situ hybridization. Amer. J. Pathol., 144, 585-591 (1994).
3. CHAMBERS, A.F. and MATRISIAN, L.M., Changing views of the role of matrix metalloproteinases in metastasis. J. nat. Cancer Inst., 89, 1260-1270 (1997).
4. COONER, W.H., MOSLEY, B.R., RUTHERFORD, C.L., JR., BEARD, J.N., POND, H.S., TERRY, W.J., IGEL, T.C. and KIDD, D.D., Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 143, 1146-1154 (1990).
5. DAVIES, B., WAXMAN, J., WASAN, H., ABEL, P., WILLIAMS, G., KRAUSZ, T., NEAL, D., THOMAS, D., HANBY, A. and BALKWILL, F., Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53, 5365-5369 (1993).
6. DECLERCK, Y.A., PEREZ, N., SHIMADA, H., BOONE, T.C., LANGLEY, K.E. and TAYLOR, S.M., Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res., 52, 701-708 (1992).
7. EGAWA, S., SOH, S., OHORI, M., UCHIDA, T., GOHJI, K., FUJII, A., KUWAO, S. and KOSHIBA, K., The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer, 79, 90-98 (1997).
8. EGAWA, S., SUYAMA, K., OHORI, M., KAWAKAMI, T., KUWAO, S., HIROKADO, K., HIRANO, S., YOKOYAMA, E., UCHIDA, T. and KOSHIBA, K., Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer, 76, 463-472 (1995).
9. FIDLER, I.J., Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res., 50, 6130-6138 (1990).
10. FUJIMOTQ, N., MOURI, N., IWATA, K., OHUCHI, E., OKADA, Y. and HAYAKAWA, T., A one-step sandwich enzyme immunoassay for human matrix, metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta, 221, 91-103 (1993).
11. GARBISA, S., SCAGLIOTTI, G., MASIERO, L., FRANCESCO, C.D., CAENAZZO, C., ONISTO, M., MICELA, M., STETLER-STEVENSON, W.G. and LIOTTA, L.A., Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res., 52, 4548-4549 (1992).
12. GLEASON, D.E. Histologic grading and clinical staging of carcinoma of the prostate. In: M. Tannenbaum (ed.), Urologic pathology: the prostate, pp. 171-197, Lea and Febiger, Philadelphia (1977).
13. GOHJI, K., FUJIMOTO, N., FUJII, A., KOMIYAMA, T., OKAWA, J. and NAKAJIMA, M., Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res., 56, 3196-3198 (1996a).
14. GOHJI, K., FUJIMOTO, N., KOMIYAMA, T., FUJII, A., OHKAWA, J., KAMIDONO, S. and NAKAJIMA, M., Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictor of recurrence in patients with urothelial carcinoma. Cancer, 78, 2379-2387 (1996b).
15. GOHJI, K., MORISUE, K., KIZAKI, T. and FUJII, A., Correlation of transrectal ultrasound imaging and the results of systematic biopsy with pathological examination of radical prostatectomy specimens. Brit. J. Urol., 75, 758-765 (1995).
16. GOHJI, K., NOMI, M., EGAWA, S., MORISUE, K., TAKENAKA, A., OKAMOTO, M., OHORI, M. and FUJII, A., Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate prostate specific antigen concentrations. Cancer, 79, 1969-1976 (1997a).
17. GOHJI, K., NOMI, M., KIZAKI, T., MORISUE, K., OKAMOTO, M., TAKENAKA, A. and FUJJI, A., An assessment of the usefulness of serum prostate-specific antigen level and cancer volume in biopsy specimens to predict the extent of prostate cancer. Brit. J. Urol., 77, 602-607 (1997b).
18. KHOKHA, R., Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J. nat. Cancer Inst., 86, 299-304 (1994).
19. LIOTTA, L.A., STEEG, P.S. and STETLER-STEVENSON, W.O., Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336 (1991).
20. MACDOUGALL, J.R. and MATRISIAN, L.M., Contributions of tumor and stromal matrix metalloproteinases to tumor progression; invasion and metastasis. Cancer Metastasis Rev., 14, 351-362 (1995).
21. NAKAJIMA, M. and CHOP, A.M., Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin. Cancer Biol., 2, 115-127 (1991).
22. r 92.000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res., 53, 5802-5807 (1993).
23. NICOLSON, G.L., Molecular mechanisms of cancer metastasis: tumor and host properties and the role of oncogenes and suppressor genes. Curr. Opin. Oncol., 3, 75-92 (1991).
24. OESTERLING, J.E., Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145, 907-923 (1991).
25. POSTE, G. and FIDLER, I.J., The pathogenesis of cancer metastasis. Nature (Lond.), 283, 139-146 (1980).
26. STAMEY, T.A., YANG, N., HAY, A.R., MCNEAL, J.E., FREIHA, F.S. and REDWINE, E., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317, 909-916 (1987).
27. r 72,000) expression in human prostate: benign and malignant tissue. Cancer Res., 53, 878-883 (1993).
28. STETLER-STEVENSON, W.O., AZNAVOORIAN, S. and LIOTTA, L., Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol., 4, 541-573 (1993).
29. STETLER-STEVENSON, W.G., KRUTZSCH, H,C. and LIOTTA, L.A., Tissue inhibitor of metalloproteinase (TIMP-2), a new member of the metalloproteinase inhibitor family. J. biol. Chem., 264, 17374-17378 (1989).
30. TERRIS, M.K. and STAMEY, T.A., Determination of prostate volume by transrectal ultrasound. J. Urol., 145, 984-987 (1991).
31. TRYGGVASON, K., HÖYHTYä, M. and PYKE, C., Type IV collagenases in invasive tumors. Breast Cancer Res. Treat., 24, 209-218 (1993).
32. UICC, TNM atlas, 3rd ed., B. Spiessl, O.H. Beahrs, P. Hermanek, R.V.P, Hutter, O. Scheibe, L.H. Sobin and G. Wagner (eds.), pp. 241-250, Springer-Verlag, Berlin (1992).
33. WINGO, P., TONG, T. and BOLDEN, S., Cancer statistics. CA Cancer J. Clin., 45, 12, (1995).
34. r 92.000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 53, 140-146 (1993).